#TradFi交易分享挑战 MRNA Price Trend Analysis:

As of May 28, 2026, Moderna (stock code: MRNA) stock price is $46.88, down 0.80% from the previous trading day. The day's price fluctuation range was $46.77 to $48.35, with a trading volume of approximately 4.22M shares and a turnover rate of 1.06%. Recently, the stock price has been influenced by factors such as clinical data for tumor vaccines, progress in flu vaccines, and financial performance, showing volatile movements. It is recommended to pay attention to the company's subsequent clinical data releases and business developments, and to make cautious decisions.
1 Recent Volatility
Recent stock price fluctuations are relatively large, with an amplitude of about 4.5%-5%, and trading volume has increased, indicating heightened market attention.
2 Long-term Trend Changes
From a peak market value of approximately $195.5 billion in 2021 to a historical low of $22.28 in November 2025, the decline exceeds 95%, with market value shrinking to less than $12 billion.
Since the beginning of 2026, the stock price has rebounded but has not yet recovered to pre-pandemic levels, currently in the $48-$49 range, still about 75% below the peak.
3 Analysis of Influencing Factors
Positive Factors:
COVID-19 vaccines (such as MNEXSPIKE) approved in multiple countries, increasing international market demand, driving revenue growth.
Progress in tumor treatments (such as mRNA-4157) and rare disease drug development, enhancing market expectations for the company's future potential.
Negative Factors:
Decline in COVID-19 demand, saturation of traditional vaccine markets, and underperformance of new vaccines (such as RSV vaccine MRESVIA).
Ongoing high R&D investment and cost pressures, with the company still operating at a loss, reporting a net loss of $1.34B in Q1 2026.

Moderna's stock price has recently rebounded due to vaccine business recovery and R&D progress, but long-term challenges remain in demand fluctuations, cost pressures, and market competition. Breakthroughs in tumor and rare disease drug development could further boost the stock price; if new vaccine market expansion falters or cost control is poor, the stock price may face renewed pressure.